10-Q: Ascend Wellness Holdings Reports 25% Revenue Increase in Q1 2024, Driven by Acquisitions and Wholesale Growth

Ascend Wellness Holdings saw a 25% increase in revenue in the first quarter of 2024, primarily due to acquisitions and expansion of wholesale operations.

Summary

• Ascend Wellness Holdings (AWH) reported a 25% increase in net revenue for the first quarter of 2024, reaching $142.4 million, compared to $114.2 million in the same period last year.
• This growth was primarily driven by $16.5 million in incremental revenue from acquisitions, including the Devi Maryland acquisition, and $15.8 million from increased wholesale operations.
• The company's gross profit increased by 46% to $52 million, with a gross margin of 36.5%, up from 31.3% in Q1 2023, due to improved utilization at cultivation facilities.
• Operating profit saw a significant increase of $2.3 million, reaching $2.6 million, compared to $0.3 million in Q1 2023.
• AWH reported a net loss of $18.2 million, slightly better than the $18.5 million loss in the first quarter of 2023.
• The company generated $3.9 million in net cash from operating activities, supported by proceeds from a note receivable collection and improved working capital management.
• AWH sold approximately 46,000 pounds of wholesale product in Q1 2024, compared to 28,000 pounds in Q1 2023.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and improved profitability metrics, but the continued net loss and risks associated with the industry temper the overall sentiment. The company is making progress but still faces challenges.

Positives

• Significant revenue growth driven by acquisitions and wholesale expansion.
• Improved gross profit margin due to better utilization of cultivation facilities.
• Substantial increase in operating profit.
• Positive net cash flow from operating activities.
• Strategic expansion through new dispensary openings and license acquisitions.

Negatives

• The company still reported a net loss of $18.2 million for the quarter.
• General and administrative expenses increased by 40%, primarily due to higher compensation costs and a reserve related to a previous transaction.
• The company experienced a decrease in revenue across legacy locations, primarily in Illinois and New Jersey, due to increased competition.

Risks

• The company faces risks related to the volatility of its stock price and liquidity.
• There are risks associated with the voting control exercised by holders of Class B common stock.
• The company's ability to attract and maintain key personnel is a risk.
• The company's ability to continue opening new dispensaries and cultivation facilities as anticipated is a risk.
• The illegality of cannabis under federal law poses a significant risk.
• The company faces risks related to compliance with state and federal regulations.
• There is uncertainty regarding the enforcement of cannabis laws.
• The company faces risks related to restricted access to banking and other financial services.
• The company faces risks related to constraints on marketing and risks related to its products.
• The company faces risks related to unfavorable tax treatment for cannabis businesses.
• The company faces risks related to proposed legislation on its tax liabilities and financial performance.
• The company faces security risks.
• The company faces risks related to infringement or misappropriation claims by third parties.
• The company faces risks related to compliance with potential future U.S. Food and Drug Administration (FDA) regulations.
• The company faces risks related to its ability to enforce its contracts.
• The company faces risks related to unfavorable publicity or consumer perception.
• The company faces risks related to material acquisitions, dispositions and other strategic transactions.
• The company faces agricultural and environmental risks.
• The company faces risks related to climate change.
• The company faces risks related to information technology systems.
• The company faces risks related to unknown health impacts associated with the use of cannabis and cannabis derivative products.
• The company faces risks related to product liability claims and other litigation to which it may be subjected.
• The company faces risks related to the results of future clinical research.
• The company faces intense competition in the industry.
• The company faces risks related to the maturation of the cannabis market.
• The company faces risks related to adverse changes in wholesale and retail prices.
• The company faces risks related to sustained inflation.
• The company faces risks related to political and economic instability.
• The company faces risks related to outbreaks of pandemic diseases, fear of such outbreaks or economic disturbances due to such outbreaks.
• The company faces risks related to general economic risks, such as the unemployment level, interest rates, and inflation, and challenging global economic conditions.

Future Outlook

The company expects continued growth to be driven by opening new operational facilities and dispensaries under current licenses, expansion of current facilities, and increased consumer demand. AWH anticipates completing the build out of three additional dispensaries in Pennsylvania, completing certain projects at the dispensaries acquired in Maryland during 2023, and funding certain expansion projects across its retail operations. The company also anticipates completing certain projects across its cultivation facilities, including the build out of a second cultivation facility in Massachusetts.

Management Comments

• Management believes that substantial doubt of our ability to continue as a going concern for at least one year from the issuance of our Financial Statements has been alleviated due to: (i) cash on hand and (ii) continued growth of sales from our consolidated operations.
• Management plans to continue to access capital markets for additional funding through debt and/or equity financings to supplement future cash needs, as may be required.

Industry Context

The results reflect the ongoing growth and competition within the cannabis industry, with AWH expanding its footprint through acquisitions and new store openings while facing pricing pressures in some established markets. The company's focus on limited license markets and vertical integration is consistent with strategies employed by other multi-state operators in the sector.

Comparison to Industry Standards

• AWH's 25% revenue growth is a strong performance compared to some of its peers in the cannabis industry, though specific comparisons are difficult without detailed competitor data.
• The improvement in gross margin to 36.5% indicates better operational efficiency, which is a key metric for cannabis companies.
• The company's focus on expanding in key markets like Massachusetts and New Jersey aligns with industry trends of targeting states with strong growth potential.
• The company's adjusted EBITDA margin of 22.8% is a positive sign, but further analysis is needed to compare it to industry benchmarks.
• The company's continued net loss highlights the challenges of profitability in the cannabis sector, which is common among many MSOs.

Management Changes

Legal Proceedings

• The Company is involved in ongoing litigation with MedMen NY, Inc. regarding a terminated investment agreement.
• The Company has established a reserve of $6.4 million related to amounts it is pursuing collecting from MedMen.

Related Party Transactions

• The company has a loan receivable with a retail dispensary partially owned by an entity managed by one of the company's founders.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and improved profitability metrics.
• Employees may benefit from the company's expansion and growth.
• Customers will have access to more dispensaries and products.
• Suppliers may see increased demand for their products and services.
• Creditors may be reassured by the company's improved financial performance.

Next Steps

• The company expects to complete the build out of three additional dispensaries in Pennsylvania.
• The company expects to complete certain projects at the dispensaries acquired in Maryland during 2023.
• The company expects to fund certain expansion projects across its retail operations.
• The company anticipates completing certain projects across its cultivation facilities, including the build out of a second cultivation facility in Massachusetts.

Key Dates

Keywords

cannabis, marijuana, dispensary, cultivation, wholesale, multi-state operator, M&A, revenue growth, financial results, cannabis industry